Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains
Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...
Zacks.com on MSN2d
Denali's ALS Study Fails to Meet Primary and Secondary Endpoints
DNLI's DNL343 fails to achieve the primary and secondary endpoints, as observed from an analysis of Regimen G of the phase II ...
ALS drugs from Denali, Calico come up short, marking setback for Healey trial
Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...
Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
Primary endpoint of overall function (ALSFRS-R) and survival, and key secondary endpoints of muscle strength and respiratory function, were not ...
GlobalData on MSN2d
Denali Therapeutics’ ALS therapy fails to meet primary endpoint in Phase II/III trial
The primary analysis included 186 subjects who received the therapy and 139 subjects who were given a placebo.
Outsourcing-pharma2d
Denali Therapeutics’ ALS drug fails to improve function and survival in phase 2/3 trial
Denali Therapeutics' DNL343 fails to slow ALS progression in phase 2/3 trial but shows safety and offers insights for future ...
BioSpace2d
Denali Suffers Another ALS Fail With Phase II/III Flop
Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...
Advnture on MSN23h
Incredible highs and a few Lowes: who are America’s greatest ever mountaineers?
Our mountaineering expert looks at America’s greatest ever mountaineers, detailing the historic ascents of the nation’s ...
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)
Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tividenofusp alfa (DNL310) for the treatment ...
Carnival Corporation's Holland America and Princess Alaska Operations Wrap Up Summer Season With Meaningful Community Volunteer Efforts
NYSE:CCL) Carnival Corporation's Holland America and Princess Alaska Operations Wrap Up Summer Season With Meaningful Community Volunteer Efforts ...
Hosted on MSN2d
Denali Reverses Its Fortunes With 'Too Early' Miss In ALS Treatment
Denali Therapeutics shares reversed higher on Tuesday after the drugmaker's ALS treatment failed in a six-month study.